Skip to main content

Table 2 Times to incident infections and incidence rates for different HPV genotypes and speciesa

From: Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study

 

Incident Infections

Mean Time to 1st Incident Infection (months)

Incident Rate (IR) per 1,000 women months at risk (wmr)

HPV Genotype:

N

%

Actuarialb(95%CI)

Crudec(95%CI)

Actuarialb(95%CI)

Crudec(95%CI)

HPV6

5

2.5

27.2 (9.2-45.2)

15.2(10.1-20.2)

0.8 (0.09-1.51)

65.9 (10.0-121.5)

HPV11

2

1.0

12.8 (12.2-13.4)

12.8(12.2-13.4)

0.3 (0.01-0.76)

78.2 (2.5-179.3)

HPV16

97

47.8

25.2 (22.0-28.3)

23.1(20.2-26.0)

15.6 (12.5-18.6)

43.3 (34.8-51.7)

HPV18

8

3.9

27.1 (13.8-40.3)

20.5(14.2-26.8)

1.3 (0.39-2.17)

48.7 (15.8-81.7)

HPV31

4

2.0

34.5 (7.4-61.6)

20.1(6.1-34.1)

0.6 (0.01-1.27)

49.8 (22.4-97.7)

HPV33

1

0.5

75.0 (75.0-75.0)

75.0(75.0-75.0)

0.2 (0.01-0.47)

13.3 (1.3-39.3)

HPV35

2

1.0

21.5 (7.7-35.3)

12.9(11.7-14.1)

0.3 (0.01-0.76)

76.9 (25.5-179.3)

HPV44

1

0.5

12.5 (12.5-12.5)

12.5(12.5-12.5)

0.2 (0.01-0.47)

80.0 (6.8-221.8)

HPV45

5

2.5

32.8 (13.9-51.6)

13.7(6.7-20.6)

0.8 (0.09-1.51)

72.4 (11.2-133.6)

HPV51

2

1.0

13.4 (0-35.7)

13.4(0-35.7)

0.3 (0.01-0.76)

74.1 (24.7-172.8)

HPV52

3

1.5

9.4 (2.0-16.8)

9.4(2.0-16.8)

0.5 (0.06-1.02)

107.1(7.4-221.7)

HPV56

2

1.0

25.4 (7.7-43.1)

42.4(0-101.0)

0.3 (0.01-0.76)

23.5 (8.6-55.7)

HPV58

4

2.0

29.0 (1.0-57.0)

13.5(4.1-22.8)

0.6 (0.01-1.27)

74.1 (42.2-143.9)

HPV59

3

1.5

17.0 (2.0-32.1)

17.0(1.9-32.1)

0.5 (0.06-1.02)

58.8 (5.8-123.4)

HPV66

2

1.0

7.6 (0-17.8)

7.6(0-17.8)

0.3 (0.01-0.76)

133.1 (38.2-305.0)

HPV70

6

3.0

11.2 (2.9-19.4)

6.3(2.0-10.6)

1.0 (0.19-1.73)

157.8 (41.9-273.8)

HPV73

2

1.0

7.6 (0-18.4)

7.6(0-18.4)

0.3 (0.01-0.76)

133.3 (38.7-305.3)

HPV82

3

1.5

9.4 (2.3-16.6)

9.4(2.3-16.6)

0.5 (0.06-1.02)

107.1 (74.1-221.7)

Multiple types

51

25.1

32.1 (26.2-37.9)

19.8(16.4-23.2)

8.2 (5.96-10.45)

50.5 (36.9-63.9)

HPV Species:

      

Species 5 (26,51,69,82)

5

2.5

11.0 (2.7-19.3)

11.0(2.7-19.3)

0.8 (0.09-1.51)

90.9 (14.9-166.9)

Species 6 (30,53,56,66)

4

2.0

16.5 (3.5-29.4)

25.0(0-56.3)

0.6 (0.01-1.27)

40.0 (1.6-78.4)

Species 7 (18,39,45,59,68,70,85)

22

10.8

27.5 (17.3-37.7)

14.6(10.5-18.7)

3.5 (2.1-5.0)

68.5 (40.9-96.2)

Species 9 (16,31,33,35,52,58,67)

111

54.7

27.5 (23.3-31.7)

22.6(19.7-25.4)

17.9 (14.6-21.2)

44.3 (36.3-52.4)

Species 10 (6,11,13,44,55,74)

8

3.9

27.0 (11.0-42.9)

14.2(11.2-17.4)

1.3 (0.39-2.17)

70.2 (23.3-117.0)

Species 11 (34,73)

2

1.0

7.6 (0-18.4)

7.6(0-18.4)

0.3 (0.01-0.76)

133.3 (38.7-305.3)

  1. a among the 203 women of the Finnish Family HPV study who had an incident infection during the FU; ball baseline HPV-negative women at risk, months at risk calculated 1) until the first incident event, or 2) as total FU months for those with no incident event (Total wmr = 6,212); conly women with an incident event (months at risk calculated until the first incident event);
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us